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1. Introduction 
Diabetes mellitus is characterized by chronically elevated serum glucose levels resulting in 
damage of several tissues (e. g. retina, kidney, nerves) due to higher protein glycation, 
retardation of wound healing, impaired insulin secretion, enhanced insulin resistance, cell 
apoptosis, and increased oxidative stress. Type 2 diabetes (T2DM), representing 90-95 % of 
all diabetic cases, is a multifactorial disease where impaired insulin secretion and the 
development of insulin resistance ultimately leads to hyperglycemia (Hengesh, 1995). The 
end of the 20th century has witnessed a dramatic increase in the number of patients 
diagnosed with diabetes worldwide. The predicted number for the year 2025 is well over 
300 million representing a 4-5 % yearly increase of the population above 20 years of age 
(Treadway et al., 2001). This striking prevalence can even be an underestimate due to 
methodological uncertainties as well as undiagnosed cases (Green et al., 2003). The highest 
increases are expected in the developing countries of Africa, Asia, and South America, while 
European populations seem to be less affected (Diamond, 2003). T2DM has been considered 
as the adult- or late-onset variant, however, the recent decade has seen the appearance and 
spreading of the disease among young people including children: this forecasts severe 
economic and health service burdens in the near future (Alberti et al., 2004; Ehtisham & 
Barrett, 2004). 
The epidemic of T2DM is in conjunction with genetic susceptibility: evidence for a genetic 
component to the disease are accumulating, and the potential of these factors in the 
treatment and prevention of diabetes has been reviewed (Barroso, 2005; Bonnefond et al., 
2010; Sladek et al., 2007; Toye & Gauguier, 2003). A similarly high contribution to this 
epidemic may originate from behavioral factors such as sedentary lifestyle, overly rich 
nutrition, and obesity (Bloomgarden, 2004). 
Especially due to its long term complications (Brownlee, 2001) like retinopathy, neuropathy, 
nephropathy, and in particular cardiovascular diseases, as well as significantly higher risk of 
myocardial infarction, stroke, gangrene, and limb amputation diabetes has become one of 
the largest contributors to disability and mortality. Although several pathomechanisms 
(Lowell & Shulman, 2005; Panunti et al., 2004; Stumvoll et al., 2005) are under investigation, 
no firm understanding of the molecular origins (Ross et al., 2004) of the disease exists. 
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Thereby, all available and investigational treatments are symptomatic. As the complications 
can first of all be attributed to the high blood glucose levels, current antidiabetic therapies 
(Table 1) aim at reaching normoglycemia. However, most of the applied oral hypoglycemic 
agents (Cheng & Fantus, 2005; Krentz & Bailey, 2005; Mizuno et al., 2008; Padwal et al., 
2005; Rendell, 2004; Uwaifo & Ratner, 2005) have several side effects and are inadequate for 
30-40 % of the patients (Wagman & Nuss, 2001). On the other hand, their efficacy is lost over 
the time, and several concerns exist regarding their safety (Israili, 2011).  
 
Drug type Molecular target Site of action Adverse effects 
Insulin sensitizers    
Metformin 
(biguanides) 
 
Unknown Liver, intestine, 
pancreas 
Gastrointestinal intolerance (diarrhea, 
nausea), lactic acidosis, decreased 
vitamin B12 level 
Thiazolidinediones 
(glitazones) 
PPAR Liver, adipose 
tissue, skeletal 
muscle 
Weight gain, ankle edema, sodium and 
fluid retention, possible bone loss 
Insulin secretagogues    
Sulfonylureas  
 
Sulfonylurea 
receptor 
Pancreas Weight gain, hypoglycemia, 
hyperinsulinemia, hypoglycemia-
provoked ischemia and arrhythmia, 
progressive decline in -cell function 
Meglitinides K-ATP channel Pancreas Weight gain, hypoglycemia, 
hypoglycemia-provoked ischemia and 
arrhythmia 
GLP-1 analogues and 
mimetics  
GLP-1 receptor Pancreas Nausea, vomiting, diarrhea 
DPP-4 inhibitors 
(glinides) 
DPP-4 Intestine, 
pancreas 
Gastrointestinal intolerance, 
nasopharyngitis, upper respiratory 
infection, urinary tract infection 
Others    
-Glucosidase 
inhibitors  
-Glucosidases Pancreas, small 
intestine  
Gastrointestinal intolerance (flatulence, 
bloating) 
SGLT2-inhibitors 
(gliflozins) 
SGLT2 Kidney Gastrointestinal intolerance (nausea), 
urinary tract infection 
Insulin  Insulin receptor Liver, muscles Weight gain, hypoglycemia 
Table 1. Main types of current therapeutic agents for T2DM and their major side effects 
(Israili, 2011; Moller, 2001) 
The complexity of T2DM offers many potential points of intervention for pharmacotherapy 
for which the main molecular targets and strategies such as insulin secretagogues, insulin 
sensitizers, hormones, inhibitors of PTP-1B, GSK3, and hepatic glucose production, methods 
for altering lipid metabolism, combination therapies, etc. have been reviewed in details 
(Israili, 2011; Morral, 2003; Nourparvar et al., 2004; Wagman et al., 2004).  
Among the numerous methods used to treat type 2 diabetes and investigated to find new 
therapeutic possibilities there are several approaches which apply carbohydrate (especially 
glucose) derivatives as well as compounds mimicking the properties of sugars. Based on our 
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experience in the chemistry of carbohydrates and glycomimetics, in this survey we 
summarize the roles of such compounds in combatting type 2 diabetes relying on the review 
literature and very recent primary scientific papers. 
2. Inhibitors of -glucosidase enzymes 
Starch and sucrose are the most important dietary carbohydrates but they are not directly 
available for the cells. They are digested in the gastrointestinal tract to monosaccharides which 
can be absorbed to the circulation to raise the serum concentration (Hanhineva et al., 2010). 
The normal blood glucose level (3.6–5.8 mM) fluctuates throughout the day, is usually lowest 
in the morning, before the first meal of the day, and rises after meals for an hour or two. 
A medically applied treatment of diabetes is to retard the absorption of glucose by inhibition 
of the carbohydrate hydrolyzing enzymes -amylase and -glucosidase in the digestive 
tract. In humans the digestion of starch, maltodextrins, and maltooligosaccharides includes 
several stages: degradation of the polymeric substrates results in shorter oligomers which 
are than cleaved by -amylase into smaller oligosaccharides. This mixture is broken down to 
monosaccharides by -glucosidase from the non-reducing end of the oligosaccharides. By 
inhibition of these enzymes the rate of glucose production can be reduced that contributes to 
diminishing the blood glucose levels, too (Tundis et al., 2010). Such inhibitors decrease 
postprandial hyperglycaemia and hyperinsulinaemia, thereby may improve sensitivity to 
insulin and release the stress on -cells (Scheen, 2003). 
Glycosidases are a long known and studied class of glycoenzymes for which an enormous 
number of compounds have been tested as inhibitors (El Ashry et al., 2000a; El Ashry et al., 
2000b; El Ashry et al., 2000c; Lillelund et al., 2002). Analogues of monosaccharides in which 
the ring oxygen is replaced by a nitrogen atom are known as iminosugars (or less properly 
azasugars) comprising both natural and synthetic molecules (Table 2) which, as the most 
potent inhibitors of glycosidases, have high pharmacological potential not only in the 
context of T2DM (Asano, 2009; Compain & Martin, 2007).  
The naturally occurring salacinol and analogous sugar mimics with a 4-thiofuranoid type 
ring (Table 2) belong to a growing class of zwitterionic glycosidase inhibitors, which attract 
great interest both as synthetic targets and applications for -glucosidase inhibition (Praly & 
Vidal, 2010).  
The positive charge on the sulfur atom in the thiosugar derivatives and in the iminosugar-
based glycosidase inhibitors at physiological pH is facilitating the binding in the active sites 
of glycosidase enzymes as a mimicry of the charge of the oxocarbeniumion-like transition 
state formed during hydrolysis of the natural enzyme substrate (Zechel & Withers, 2000). 
The stabilizing electrostatic interactions between the ammonium (protonated nitrogen) or 
sulfonium (positively charged sulfur) moieties and an active-site carboxylate residue are 
considered to be a possible mechanism of action of these inhibitors (Mohan & Pinto, 2007). 
Three competitive inhibitors of -glucosidases: acarbose, miglitol, and voglibose (de Melo et 
al., 2006) (Table 3) are used as drugs in the treatment of T2DM under various brand names. 
These compounds are known to inhibit a wide range of glycosidases. In the absence of 
specificity and because of the known serious side effects, the applications of these first 
generation iminosugar drugs are limited. Current investigations aim at discovering safer, 
more specific, and effective iminosugar based derivatives not only as hypoglycemic agents 
but for several other purposes among others in oncology, as antivirals, and against cystic 
fibrosis as reviewed in (Home et al., 2011). 
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Table 2. Select iminosugar and thiosugar type inhibitors and their effect against 
-glucosidases originating from mammalian gastrointestinal tract 
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Name Structure Side-effect 
Acarbose 
Approved in 1995 
H
N
O
O
O
O
O
OH
OH
HO
OH OH OHHO
H3C
HO HO HO
HO HO HO
 
Flatulence  
(78% of the patients) 
Diarrhea  
(14% of the patients) 
Miglitol 
Approved in 1996 N
OH
HO
HO
HO
OH
 
Diarrhea, gas, soft 
stools, stomach pain 
Voglibose 
Approved in 1997 
H
N
OHHO
HO
OH
OH
OH
HO
 
Diarrhea, stool loss, 
meteorism, upset 
stomach 
Table 3. -Glucosidase inhibitors in the clinical practice against T2DM 
3. Inhibitors of renal sodium-glucose cotransporters 
The mammalian kidney plays an important role in the maintenance of energy balance of the 
organism. In healthy individuals 180 g/day of D-glucose is filtered from plasma through the 
glomerulus, which is completely reabsorbed in the renal proximal tubules to the blood-
stream, thereby preventing the loss of glucose in the urine (Wright, 2001). This reabsorption 
process is mediated by two sodium dependent glucose cotransporters (SGLTs). SGLT1 is a 
high-affinity, low-capacity glucose/galactose transporter located predominantly in the small 
intestine, but is also present in the S3 segment of the proximal tubule in the kidney, as well 
as in the heart. The primary function of SGLT1 is the absorbtion of dietary glucose in the 
intestine, however it shares in the renal glucose transport in the kidney and regulates 
cardiac glucose transport in the heart, as well. SGLT2 is a low affinity, high capacity glucose 
transporter specifically expressed in the S1 segment of the proximal convoluted tubule. 
SGLT2 is responsible for ~90 % of renal glucose reabsorption, while SGLT1 plays only an 
auxiliary role in this process (Boldys & Okopien, 2009; Idris & Donnelly, 2009; Washburn, 
2009b). Genetic studies demonstrated that defects of SGLT2 but in a lesser extent of SGLT1 
genes had neither adverse effects on kidney function as well as carbohydrate metabolism, 
nor hypoglycaemia (Handlon, 2005; Santer & Calado, 2010; Wright, 2001). 
Nowadays sodium-glucose cotransporters have received remarkable attention as new drug 
targets for the treatment of diabetes (Bailey, 2011). Considering the exclusive expression of 
SGLT2 in the kidney and its predominant role in renal glucose recovery, most 
pharmaceutical investigations have focused primarily on selective SGLT2 inhibition to 
facilitate benign glucosuria (Santer & Calado, 2010; Washburn, 2009b). In contrast to the 
currently applied diabetic therapies most of which aim at insulin resistance and insulin 
deficiency, targeting SGLT2 is an insulin-independent strategy based on enhanced renal 
glucose excretion and, consequently, lowering plasma glucose levels without severe side 
effects (Isaji, 2007). 
In recent years aromatic, heteroaromatic, and fused aromatic O- and N-glucopyranosides, C-
glucopyranosyl derivatives, anomeric spirocycles, as well as their congeners with modified 
sugar rings have been developed as SGLT2 inhibitors (Handlon, 2005; Idris & Donnelly, 
2009; Isaji, 2007; Nomura, 2010; Vaidya & Goyal, 2010; Washburn, 2009a; Washburn, 2009b). 
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R = H unless indicated otherwise 
Entry R’ Entry R’ Entry R’ 
1. 
OH
OH
O
OH
2. 
CH3
OH
O
O  
3. 
OMe 
Phlorizin
35.6* (Meng et al., 2008)
18.6** (Katsuno et al., 2007)
T-1095
R = COOMe (prodrug form)
T-1095A 
R = H (active form)
50 (Handlon, 2005)
6.6* (Meng et al., 2008)
Sergliflozin 
R = COOEt (prodrug form) 
Sergliflozin-A 
R = H (active form) 
 9.2* (Meng et al., 2008) 
2.39** (Katsuno et al., 2007) 
4. 
N
N
 
5. 6. 
 
0.1 (Handlon, 2005) Remogliflozin etabonate
R = COOEt (prodrug form)
Remogliflozin
R = H (active form)
12.4** (Fujimori et al., 2008)
BI 44847 (Washburn, 2009b) 
7. 
N
Me
Me
Me
F
8. 
N
N
N
Et 
9. 
NH
O
 
3 (Handlon, 2005) 8 (Handlon, 2005) 20 (Handlon, 2005) 
Table 4. Selected O-glucopyranoside type inhibitors of SGLT2 (IC50, EC50, Ki  values [nM]) 
The first class of potential SGLT2 inhibitors to be explored was the O-glucosides derived 
from the structure of phlorizin (Table 4, Entry 1) of natural origin isolated from the root bark 
of the apple tree (Ehrenkranz et al., 2005). Phlorizin lowers plasma glucose levels and 
improves insulin resistance by increasing renal glucose excretion (Isaji, 2007). However, it is 
not considered as an antidiabetic drug because of its nonselective inhibition against SGLTs 
as well as its metabolic instability due to hydrolysis by glucosidase enzymes in the intestinal 
tract that prevented oral administration (Washburn, 2009a). In addition, enzymatic release 
of the aglycone phloretin, a micromolar inhibitor of sodium-independent facilitative glucose 
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transporters (GLUTs), could potentially inhibit GLUT-mediated cellular uptake of glucose 
(Ehrenkranz et al., 2005; Washburn, 2009a). Because of the poor bioavailability and the 
aforementioned undesirable effects of phlorizin, initial efforts entailed exploring more stable 
and selective O-glucoside analogues of this compound. 
T-1095 (Table 4, Entry 2) is a methyl carbonate prodrug which,  after oral administration, is 
rapidly converted to an active metabolite, T-1095A showing high affinity and plausible 
selectivity against human SGLT2 (Handlon, 2005). Development of T-1095 reached phase II 
clinical trials but was subsequently discontinued (Isaji, 2007). 
The -D-glucosides in which the aglycone moiety is a phenyl ring substituted in ortho 
position by a benzyl group represent a promising type of O-glucoside candidates (Entries 3 
and 4). Sergliflozin (Entry 3), an ethyl carbonate prodrug, emerged from this series to enter 
clinical trials (Isaji, 2007). According to the in vitro assay, its active form is a highly potent 
and 296-fold more selective inhibitor for human SGLT2 over SGLT1 (Katsuno et al., 2007). 
Heteroaromatic O-glucosides are the next potent series of SGLT2 inhibitors. Among 
pyrazole derivatives remogliflozin (Entry 5) showed a reassuring 365-fold selectivity for 
SGLT2 versus SGLT1 in vitro (Fujimori et al., 2008), and reached clinical developments (Isaji, 
2007). In addition, an analogue of remogliflozin (Entry 6) presumably entered clinical trials 
as BI 44847 (Washburn, 2009b). 2-Pyridyl-O-glucoside (Entry 7) with a potency of 3 nM 
against human SGLT2 represent an additional highly active compound of this class 
(Handlon, 2005). 
Efficacy of a series of benzofused heterocyclic derivatives was also investigated and, for 
example, benzotriazole and indole O-glucosides (Entries 8 and 9, respectively) were found 
to strongly inhibit human SGLT2 (Handlon, 2005). 
Susceptibility of O-glucosides to enzymatic degradation by glucosidases impacted 
bioavailability and duration of action (Washburn, 2009b). Therefore, remarkable attention 
has been paid to metabolically more stable C-glucopyranosyl derivatives.  
Compounds containing a diarylmethane aglycone represent the first type of this class (Table 
5). According to the SAR the benzyl substituent in meta position of the central aryl ring is 
more favourable compared to the ortho attached derivatives of high activity in case of O-
glucosides (Washburn, 2009a; Washburn, 2009b). At present, dapagliflozin (Entry 1) with 
considerable in vitro as well as in vivo activity is the most advanced SGLT2 inhibitor in phase 
III clinical trials and has become a leading structure for further inhibitor design (Washburn, 
2009a; Washburn, 2009b). 
Additional SAR exploration revealed that introduction of an appropriate ortho substituent 
at the proximal phenyl ring adjacent to the glycosidic bond is beneficial in respect of 
inhibitory efficiency (Entry 2) (Washburn, 2009a). For example, propargyl ether derivative 
(Entry 3) exhibited sub-nanomolar activity and a more than 3300-fold selectivity for SGLT2 
(Xu et al., 2010). 
Replacement of the distal phenyl group with fused rings resulted in a new potent inhibitor 
type. For example, 1:1 choline complex of azulene (Entry 4) as well as 1:1 L-proline complex 
of benzothiophene (Entry 5) derivatives appeared as clinical candidates (Washburn, 2009b). 
Modification of dapagliflozin by replacing the distal aryl ring by heterocycles led to the 
discovery of canagliflozin (Entry 6) which obtained the second highest interest in clinical 
developments (Nomura et al., 2010). 
Recently, along this line, the structure of dapagliflozin was modified by other heterocycles 
such as thiazole (Song et al., 2011), 1,3,4-thiadiazole (Lee et al., 2010b), pyridazine (Kim et 
al., 2010), and pyrimidine (Lee et al., 2010a) moieties. Among them, the thiazole derivative  
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Entry R Entry R Entry R 
1. 
 
2. 
 
3. Cl
Et
O  
Dapagliflozin
BMS-512148
1.1* (Meng et al., 2008)
0.49 (Song et al., 2011)
6.7 (Xu et al., 2010)
1.4 (Robinson et al., 2010)
1.3* (Nomura, 2010) 0.3 (Xu et al., 2010) 
4. 
 
5. 
 
6. 
 
YM-543 = 1:1 complex
with choline
8.9 (Washburn, 2009b)
ASP1941 = 1:1 complex
with L-proline
8.4 (Washburn, 2009b)
Canagliflozin 
TA-7284 
2.2 (Nomura et al., 2010) 
7. 
 
8. 9. 
 
0.72 (Song et al., 2011) 6.5 (Handlon, 2005) 6 (Washburn, 2009b) 
10. 11. 12. 
S
Me
 
10 (Zhou et al., 2010) 1.4 (Washburn, 2009b) 2 (Washburn, 2009b) 
 
Table 5. C-glucopyranosyl compounds as SGLT2 inhibitors (IC50, EC50 values [nM]) 
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(Entry 7) displayed the best result, however, according to its in vitro (IC50 = 0.72 nM) as well 
as in vivo activity, it was less potent than dapagliflozin (IC50 = 0.49 nM) (Song et al., 2011). 
From C-glucosyl hetarenes containing a central heterocyclic ring such as pyrazine, indole, 
benzisothiazole, and benzothiophenes (Entries 8-12, respectively) the latter two proved most 
efficient (Washburn, 2009b). 
N-Glucopyranosides represent an other series of SGLT2 inhibitors with probably higher 
metabolic stability as compared to O-glucopyranosides. Among these derivatives 
benzylated aniline-, pyrrole-, and indole N-glucosides (Table 6, Entries 1-4, respectively) are 
potent orally active SGLT2 inhibitors (Washburn, 2009b).  
O-Spiroketal C-arylglucosides (Entries 5 and 6) which combine the character of both O-
glucosides and C-glucosyl derivatives, show good inhibitory activity (Lv et al., 2009) and 
high selectivity (Washburn, 2009b) for SGLT2 which can be attributed, in part, to a greater 
conformational constraint imposed by the spiro-annelated ring system.  
In the quest of new candidates for SGLT2 inhibition the modification of the sugar part of the 
molecules is a further possibility. Replacement of the ring oxygen by a sulfur atom provided 
new potent 1,5-anhydro-1-thio-D-glucitol derivatives (Table 7, Entries 1-3) (Washburn, 
2009b). TS-071 (Entry 1) showed excellent urinary glucose excretion in dogs and is currently 
undergoing phase II clinical trials (Kakinuma et al., 2010). Modification of the glucose 
moiety by substituting the hydroxyl groups attached to either C-4 or C-6 with fluorine 
(Entries 4 and 5) also resulted in effective molecules (Washburn, 2009b). Replacement of the 
hydroxymethyl side chain of the glucose part with a methyl- or methylsulfanyl group 
(Entries 6 and 7, respectively) provided molecules with good inhibitory effect, from which 
LX4211 (Entry 7) is a clinical candidate (Washburn, 2009b). Further transformation of the  
 
Entry  Entry  
1. 2. O
OH
HO
HO N
OH
Et
Me  
 2.9 (Washburn, 2009b) 1.1 (Washburn, 2009b) 
3. 4. 
 
 0.9 (Washburn, 2009b) 2.3 (Washburn, 2009b) 
5. 6. 
 
 1.5 (Washburn, 2009b) 0.3 (Lv et al., 2009) 
Table 6. Select compounds of N-glucopyranosides, N-glucopyranosyl heterocycles, and 
anomeric spirocycles (IC50 [nM]) 
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side chain of the sugar moiety as in the C-5-spirocyclic analogues (Entries 8 and 9) as well as 
removal of the 4-OH from the glucose ring (Entry 10) furnished compounds exhibiting 
SGLT2 inhibitory effect in the low nanomolar range (Robinson et al., 2010). 
 
 
Entry  Entry  
1. 
S
OH
HO
HO
OH
Me
OEt
OMe
2. 
 
 TS-0712.26 (Kakinuma et al., 2010)
10 (Washburn, 2009b) 
3. 
 
4. 
O
OH
HO
F OH
S
Cl  
 12 (Washburn, 2009b) 5 (Washburn, 2009b) 
5.  6. 
 
 31 (Washburn, 2009b) 2.4 (Robinson et al., 2010) 
7. 8. 
 
 LX4211 (Washburn, 2009b) 3.4 (Robinson et al., 2010) 
9. 10. 
 
 3.0 (Robinson et al., 2010)  21 (Robinson et al., 2010) 
 
 
Table 7. Miscalleneous compounds with modifications in the glucose unit as inhibitors of 
SGLT2 (IC50, [nM]) 
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4. Glucose analogue inhibitors of glycogen phosphorylase 
The liver accounts for ~90 % of the body's endogenous glucose production. Hepatic glucose 
is formed via two pathways: glycogenolysis (release of monomeric glucose from the 
glycogen polymer storage form) and gluconeogenesis (de novo synthesis of glucose from C-3 
precursors). Hepatic glucose output is elevated in type 2 diabetic patients, therefore, 
modulation (mostly inhibition) of one or more of the respective biochemical pathways may 
contribute to diminishing blood sugar levels. Targets for this can be the glucagon receptor 
(enhances hepatic glucose output), GCK (catalyzes the first step of glycolysis), 6PF-2-K/F-
2,6-P2ase (regulator of glycolytic and gluconeogenic rates through production of F-2,6-P2), 
G-6-Pase (catalyzes the last step of gluconeogenesis), F-1,6-P2ase (regulates gluconeogenic 
rates), GSK3 (inhibits glycogen synthase), and glycogen phosphorylase (GP, catalyzes the 
conversion of glycogen to glucose-1-phosphate monomers) (Morral, 2003). Current evidence 
indicates that glycogenolysis is an important contributor (~75 %) to the production of 
glucose by the liver. Furthermore, a substantial portion of glucose formed by 
gluconeogenesis is cycled through the glycogen pool prior to efflux from the liver cells 
(Andersen et al., 1999). As GP is the rate determining enzyme of glycogen breakdown 
(Kurukulasuriya et al., 2003; Ross et al., 2004) its pharmacological inhibition has been 
regarded as an effective therapeutic approach to treating diseases caused by abnormalities 
in glycogen metabolism, such as type 2 diabetes (Oikonomakos, 2002; Somsák et al., 2003; 
Somsák et al., 2005), myocardial ischemia (Tracey, W. et al., 2003; Tracey, W. R. et al., 2004), 
cerebral ischemia (Sun & Xu, 2010), and tumors (Geschwind et al., 2004; Schnier et al., 2003).  
Glycogen phosphorylases (existing as ‘muscle’, ‘brain’, or ‘liver’ isoforms) are allosterically 
regulated enzymes consisting of a dimeric arrangement of two identical subunits related to 
each other by a C2 symmetry. Protein crystallographic studies (Chrysina, 2010; 
Oikonomakos, 2002) revealed the existence of six binding sites in GP (Fig. 1): the catalytic, 
the inhibitor, the allosteric, the glycogen storage, and the new allosteric sites, as well as the 
newly discovered benzimidazole site (Chrysina et al., 2005). Each binding site can be 
targeted by small molecules, and a large variety of inhibitors were tested as described in 
recent reviews (Loughlin, 2010; Oikonomakos & Somsák, 2008; Somsák et al., 2008).  
Physiological investigations with glycogen phosphorylase inhibitors in the context of T2DM 
have recently been reviewed (Agius, 2010). 
Under physiological conditions glucose (Fig. 2) serves as a regulator of GP since the less 
active T state of the enzyme is stabilized (Board et al., 1995) by its weak binding to the 
catalytic centre. This has raised the possibility to search for glucose derivatives with much 
higher affinity to the active site. A large variety of glucose based compounds were 
synthesized and tested mainly against the prototype of the GP enzymes, the best available 
rabbit muscle GP (Chrysina, 2010). 
For the inhibitory glucose derivatives (Gimisis, 2010; Praly & Vidal, 2010; Somsák, 2011; 
Somsák et al., 2003; Somsák et al., 2005) protein crystallography showed primary binding to 
the catalytic site of the enzyme. Some glucose analogues can also occupy the new allosteric 
site (Oikonomakos et al., 2002), and the benzimidazole-site was evidenced by a 2-(-D-
glucopyranosyl)-benzimidazole (Chrysina et al., 2005). 
The studied O-, and S-glucopyranosides proved very weak inhibitors with Ki values in the 
2000-25000 M and 650-21100 M, respectively (Somsák et al., 2003; Somsák et al., 2005).  
Extensive investigation of N-glucopyranosylamide type compounds (Table 8, Entries 1-4) 
revealed that a) the NHCONHCO linker between the sugar and the aromatic part of the 
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Fig. 1. A schematic diagram of the muscle GPb dimeric molecule viewed down the 
molecular dyad. (The positions are shown for the catalytic, allosteric, glycogen storage, 
inhibitor, new allosteric, and benzimidazole sites. The catalytic site, marked by 2--D-
glucopyranosyl benzimidazole, is buried at the center of the subunit and is accessible to the 
bulk solvent through a 15 Å-long channel. Binding of the competitive inhibitor 
benzimidazole promotes the less active T state through stabilization of the closed position of 
the 280s loop (shown in white). The allosteric site, which binds the activator AMP (indicated 
in the figure), is situated at the subunit–subunit interface some 30 Å from the catalytic site. 
The inhibitor site or caffeine binding site, which binds purine compounds such as caffeine 
and flavopiridol (indicated) is located on the surface of the enzyme some 12 Å from the 
catalytic site and, in the T state, obstructs the entrance to the catalytic site tunnel. The 
glycogen storage site (with bound maltopentaose) is on the surface of the molecule some 30 
Å from the catalytic site, 40 Å from the allosteric site and 50 Å from the new allosteric 
inhibitor site. The new allosteric or indole binding site, located inside the central cavity, 
formed on association of the two subunits, binds indole-2 carboxamide analogs, N-benzoyl-
N’--D-glucopyranosyl urea, and benzimidazole (indicated). The novel binding site with 
bound benzimidazole, also located on the surface of the molecule, is some 31 Å from the 
catalytic site, 32 Å from the allosteric site, and 32 Å from the indole site. (Figure by courtesy 
of N. G. Oikonomakos and E. D. Chrysina.) 
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-D-glucose -D-glucose
Ki = 1700 M Ki = 7400 M
 
Fig. 2. Structure of - and -D-glucose and their inhibition constants with RMGPb. 
 
Entry Compound 
R 
A B C 
 (Somsák, 2011;
 Somsák et al., 2008)   
1. 
O
OH
HO
HO
OH
H
N
O
R CH3 32 81 10 
2. 
O
OH
HO
HO
OH
H
N
O
H
N
R H 140 18 5.2 
3. 
O
OH
HO
HO
OH
H
N
O
H
N
O
R - 4.6 0.35 
4. 
O
OH
HO
HO
OH
H
N
O
H
N
O
H
N
R - 21 - 
 (Gimisis, 2010) -CH3 -(CH2)2SCH3 
 
5. 
O
OH
HO
HO
OH
H
N
O
H
N
COOH
R 510 1200 350 
 
(Alexacou et al., 2010; 
 Deleanu et al., 2008)  F Cl 
6. 
O
OH
HO
HO
OH
H
N
S
H
N
N
H
C
R 33 5.7 28 
Table 8. Inhibition of RMGPb by N-glucopyranosidic derivatives (Ki [M]) 
compounds and b) a large hydrophobic substituent (compare columns B and C) make the 
best inhibitor (Entry 3C), actually the first glucose analogue in the nanomolar inhibition 
range. Other structures, e. g. those in Entries 1-2A, are much less efficient. For further 
detailed analysis of structure-activity relationships of analogous compounds see (Somsák et 
al., 2008). N-Glucopyranosylamides incorporating natural L-amino acids (Entry 5) proved 
weaker inhibitors (Gimisis, 2010), although the hydrophobicity of the appendage seems to 
play an important role in this series, as well (compare Entries 5A and 5B to 5C). Very 
recently thiosemicarbazone type inhibitors (Entry 6) have been published with inhibitory 
efficiency in the low micromolar range (Alexacou et al., 2010; Deleanu et al., 2008). 
Among 1-glucopyranosyl-1,2,3-triazoles (Table 9, Entries 1-3), which can be regarded as 
non-classical bioisosteres of N-glucopyranosylamides (Table 8, Entry 1), some low 
micromolar inhibitors were found (Somsák, 2011) which again show the preference for a  
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Entry Compound  R Ki [M] 
 (Somsák, 2011)   
1. 
O
OH
HO
HO
OH
N
N
N R
 
 
151 
2. 16 
3. -CH2OH 14 
 
(Gimisis, 2010; 
Praly & Vidal, 2010)   
4. O
OH
HO
HO
OH
N
N
N
N
NH2
  310 
5. 
O
OH
HO
HO
OH
N
N
N
H
N
O
NH2
  170 
6. 
O
OH
R
HO
OH
N NH
O
O
 
OH 6.1 
7. F 3460 
8. 
O
OH
R
HO
OH
N NH
O
O
F
 
OH 5.5 
9. F 3670 
10. 
O
OH
R
HO
OH
N N
O
NH2
 
OH 7.7 
11. F 4010 
12. O
OH
F
HO
OH
N N
O
H
N
O
  46 
13. O
OH
HO
HO
OH
N NH
NH
O
O
  76 
Table 9. Inhibition of RMGPb by N-glucopyranosyl heterocycles 
large aromatic moiety (compare Entries 1 and 2 in Table 9). Interestingly, a polar appendage 
also led to an inhibitor of similar efficiency (Entry 3). N-Glucopyranosyl derivatives of the well 
known nucleobases were also tested towards GP (Gimisis, 2010): while the purine derivatives 
(Entries 4 and 5) proved modest inhibitors, pyrimidines in Entries 6, 8, and 10 showed binding 
in the low micromolar range. Modification of the glucose moiety by replacing the 3-OH of 
these compounds by fluorine (Entries 7, 9, and 11) weakened the inhibition by a factor of ~600 
on an average. On the other hand, introduction of a hydrophobic group (compare Entries 11 
and 12) was beneficial in this series, as well, resulting in an almost 100-fold stronger inhibitor. 
Enlarging the heterocyclic ring to a seven-membered one (Entry 13) gave a weaker inhibitor in 
comparison to the six-membered pyrimidine derivatives.  
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Entry Compound   Ki [M] 
 (Somsák et al., 2003)   
1. 
O
OH
HO
HO
OH
CONHR  
R = H 440 
2. R = CH3 160 
 (Somsák, 2011)   
3. O
OH
HO
HO
OH
CN   130 
4. O
OH
HO
HO
OH
C(=NH)NHOH     No inhibition 
5. 
O
OH
HO
HO
OH
X
O
 
X = CH2   52 % at 100 M 
6. X = NH 3.5 
7. O
OH
HO
HO
OH
N
N
NHN
    No inhibition 
8. 
O
OH
HO
HO
OH
X
N
 
X = S 76 
9. X = NH 9 
10. O
OH
HO
HO
OH
O
NN
    10 % at 625 M 
11. O
OH
HO
HO
OH
N
ON
  38 
12. O
OH
HO
HO
OH
N
NO
  2.4 
Table 10. Inhibition of RMGPb by C-glucopyranosyl compounds 
Glucose derivatives with a substituent attached by a carbon-carbon bond (Table 10, Entries 
1-4) showed weak or no inhibition. A comparison of the C-glucosyl compound in Entry 5 to 
the analogous N-glucosyl derivative in Entry 6 demonstrates that the more rigid amide type 
structure binds stronger to GP than its counterpart with the CH2-group lending more 
flexibility to the molecule. In a series of C-glucopyranosyl heterocycles (Entries 7-12) the size 
and nature of the heterorings proved very important showing stronger inhibition for the 
larger ones (compare Entries 7-9), and especially for the benzimidazole in Entry 9. Among 
oxadiazole derivatives of equal size (Entries 10-12) the constitution of the heterocycle 
proved decisive to give the low micromolar inhibitor of Entry 12. 
The anomeric spiro-hydantoin and -thiohydantoin (Table 11, Entries 1 and 2, respectively) 
belong to the first efficient compounds of early GP inhibitor design. Changing the sugar part 
from glucose to xylose (by removal of the CH2OH substituent, Entries 3 and 4) resulted in 
complete loss of inhibition. Reversal of the spiro-configuration (compare Entries 1 and 5) as 
well as spiro-annelation of a six-membered ring (Entry 6) gave compounds with 
significantly weaker binding (Somsák et al., 2003). Extension of the anomeric spirocycles by 
further ring-condensations as in Entries 7 and 8 produced practically inefficient structures 
(Gimisis, 2010). Substitution by aromatic groups in the spiro-isoxazolines (Entries 9 and 11) 
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and spiro-oxathiazoles (Entries 10 and 12) gave good inhibitors and the naphthyl derivatives 
(Entries 11 and 12) are among the best known glucose derived compounds (Somsák, 2011).  
Contrary to -glucosidases, iminosugar type compounds with 5-7 membered rings do not 
show significant inhibition against GP enzymes: e. g. nojirimicin has no effect, for 1-deoxy-
nojirimicin Ki = 55000 M (for the structures see Table 2) (Compain et al., 2007). There are a 
few exceptions to this such as DAB and isofagomine derivatives (Fig. 3) (Praly & Vidal, 
2010; Somsák et al., 2008; Somsák et al., 2003). A comprehensive tabulation of glycogen 
phosphorylase inhibition studies with iminosugars can be found in (Compain et al., 2007). 
 
 
Entry Compound  X Ki [M] 
 (Somsák et al., 2003)   
1. O
HO
HO
HO
OH
N
H
H
N
X
O
 
O 3.1 
2. S 5.1 
3. O
HO
HO
HO
N
H
H
N
X
O
 
O   No inhibition 
4. S   No inhibition 
 
5. 
O
HO
HO
HO
OH
HN
NH
O
O
  320 
6. 
O
HO
HO
HO
OH
N
H
H
N O
O
  59 
 (Gimisis, 2010)   
7. 
O
HO
HO
HO
OH
O
N
NH
O
O   ~2100 
8. 
O
HO
HO
HO
OH
N
O
HN
O
O
  ~1700 
 (Somsák, 2011)   
9. O
HO
HO
HO
OH
O N
X  
CH2 19.6 
10. S 26 
11. O
HO
HO
HO
OH
O N
X  
CH2 0.63 
12. S 0.16 
 
 
Table 11. Inhibition of RMGPb by anomeric spirocycles 
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NH
HO
HO
OH
NHHO
HO
OH
NHO
HO
OH
DAB
1,4-dideoxy-1,4-imino-D-arabinitol isofagomine N-(3-phenylpropyl)-isofagomine
IC50 [M]
RMGPb        0.39                                         1.21                                            0.84 
RLGPa         0.37                                         0.68                                            1.22
PLGPa         0.49                                         0.67                                            0.85
 
Fig. 3. Iminosugar type inhibitors of various GP enzymes 
Miscellaneous sugar derivatives including further O-, S-, and N-glucopyranosides, C-
glucopyranosyl compounds, S-glucopyranosyl sulfonamide, homo- and heteromultivalent 
glucose derivatives, as well as other sugar type compounds with significantly lower 
efficiency as compared to the above listed ones were also reviewed (Praly & Vidal, 2010; 
Somsák, 2011; Somsák et al., 2008; Somsák et al., 2003). 
While no physiological investigations with glucose analogue inhibitors of GP can be found 
in the literature, very recently it has been demonstrated that glucopyranosylidene-spiro-
thiohydantoin (Table 11, Entry 2) is effective in lowering blood glucose levels and restoring 
hepatic glycogen content in streptozotocin-induced diabetic rats (Docsa et al., 2011).  
5. Conclusion 
This survey provided an overview of carbohydrate derivatives and sugar like compounds 
(glycomimetics) which are employed in current therapies or investigated as potential future 
medications for type 2 diabetes mellitus. Although these applications and explorations do 
not exceed the symptomatic level of treatments characteristic of present curing, they 
promise the possibility of broadening the arsenal of the physician. Together with several 
other carbohydrate-based therapeutics these drugs and studied molecules pave the way for 
a more extensive use of saccharides in medicine. 
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7. Abbreviations 
DPP-4 dipeptidyl-peptidase-4 6PF-2-K 6-phosphofructo-2-kinase 
F-1,6-P2ase fructose-1,6-bisphosphatase PLGP pig liver glycogen phosphorylase 
F-2,6-P2 fructose-2,6-bisphosphate PPAR peroxisome proliferator-activated receptor  
G-6-Pase glucose-6-phosphatase PTP-1B protein tyrosin phosphatase-1B 
GCK glucokinase RLGP rat liver glycogen phosphorylase 
GLP-1 glucagon-like peptide-1 RMGP rabbit muscle glycogen phosphorylase 
GLUT glucose transporter SAR structure-activity relationship 
GP glycogen phosphorylase SGLT sodium dependent glucose transporter 
GPI glycogen phosphorylase inhibitor T2DM type 2 diabetes mellitus 
GSK3 glycogen synthase kinase-3   
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